Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England.
Saved in:
| Title: | Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England. |
|---|---|
| Authors: | Mugwagwa T; Pfizer Ltd, Tadworth, UK., Averin A; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Atwood M; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Sato R; Pfizer Inc, Collegeville, PA, USA., Vyse A; Pfizer Ltd, Tadworth, UK., Campling J; Pfizer Ltd, Tadworth, UK., Weycker D; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Slack M; School of Medicine & Dentistry, Griffith University, Gold Coast Campus, Southport, Queensland, Australia., Ellsbury G; Pfizer Ltd, Tadworth, UK., Mendes D; Pfizer Ltd, Tadworth, UK. |
| Source: | Expert review of vaccines [Expert Rev Vaccines] 2022 Sep; Vol. 21 (9), pp. 1331-1341. Date of Electronic Publication: 2022 Aug 08. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101155475 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8395 (Electronic) Linking ISSN: 14760584 NLM ISO Abbreviation: Expert Rev Vaccines Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35929956 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Mugwagwa+T%22">Mugwagwa T</searchLink>; Pfizer Ltd, Tadworth, UK.<br /><searchLink fieldCode="AU" term="%22Averin+A%22">Averin A</searchLink>; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA.<br /><searchLink fieldCode="AU" term="%22Atwood+M%22">Atwood M</searchLink>; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sato+R%22">Sato R</searchLink>; Pfizer Inc, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Vyse+A%22">Vyse A</searchLink>; Pfizer Ltd, Tadworth, UK.<br /><searchLink fieldCode="AU" term="%22Campling+J%22">Campling J</searchLink>; Pfizer Ltd, Tadworth, UK.<br /><searchLink fieldCode="AU" term="%22Weycker+D%22">Weycker D</searchLink>; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA.<br /><searchLink fieldCode="AU" term="%22Slack+M%22">Slack M</searchLink>; School of Medicine & Dentistry, Griffith University, Gold Coast Campus, Southport, Queensland, Australia.<br /><searchLink fieldCode="AU" term="%22Ellsbury+G%22">Ellsbury G</searchLink>; Pfizer Ltd, Tadworth, UK.<br /><searchLink fieldCode="AU" term="%22Mendes+D%22">Mendes D</searchLink>; Pfizer Ltd, Tadworth, UK. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101155475%22">Expert review of vaccines</searchLink> [Expert Rev Vaccines] 2022 Sep; Vol. 21 (9), pp. 1331-1341. <i>Date of Electronic Publication: </i>2022 Aug 08. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101155475 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8395 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214760584%22">14760584 </searchLink><i>NLM ISO Abbreviation: </i>Expert Rev Vaccines <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35929956 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/14760584.2022.2104250 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1331 Titles: – TitleFull: Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Mugwagwa T – PersonEntity: Name: NameFull: Averin A – PersonEntity: Name: NameFull: Atwood M – PersonEntity: Name: NameFull: Sato R – PersonEntity: Name: NameFull: Vyse A – PersonEntity: Name: NameFull: Campling J – PersonEntity: Name: NameFull: Weycker D – PersonEntity: Name: NameFull: Slack M – PersonEntity: Name: NameFull: Ellsbury G – PersonEntity: Name: NameFull: Mendes D IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: 2022 Sep Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1744-8395 Numbering: – Type: volume Value: 21 – Type: issue Value: 9 Titles: – TitleFull: Expert review of vaccines Type: main |
| ResultId | 1 |